ClinicalTrials.gg
RecruitingNCT07004452Updated Jun 4, 2025

Multi-modal Adverse Events Prediction for Premature Coronary Heart Disease Trial: MAP-CHD Trial

An observational study in Premature Coronary Heart Disease, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by China National Center for Cardiovascular Diseases · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases — 12 open to participants now, 13 under way, none of them phase 3. Coronary Disease · China National Center for Cardiovascular Diseases.

Planned enrollment
6th of 12
5,000 · median 5,000
Started
2025
with 5 others
Observational
12 of 25
4 open now
Primary completion
2027-07
later than 8 of 12 live
Registered
19th of 25
by date

Among the 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases, this one is the 6th largest by planned enrollment of the 12 observational ones that give a count, is one of 6 that started in 2025, is one of 12 observational ones, reaches primary completion later than 8 of the 12 other live ones, and was the 19th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

12 of the 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases, or all of them as a file.
02

Study summary

The goal of this observational cohort study is to establish a risk prediction model for adverse events in Chinese individuals under 45 years old with premature coronary artery disease. The main questions it aims to answer are:

  • What are the major risk factors for poor prognosis in Chinese patients with premature coronary artery disease?
  • What is the difference in the prognosis of patients with premature coronary heart disease with different phenotypes? Participants taking no mandatory intervention will be followed up for 2 year, with blood tests at 1 year and outpatient or telephone interviews at other timepoints.
03

Conditions studied

  • Premature Coronary Heart Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Eligible participants are CAD patients aged 18-45 years confirmed by coronary angiography or other imaging modalities, including those with stable/unstable angina or myocardial infarction.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-45 years;
  • Clinically confirmed CAD with ≥50% luminal stenosis in at least one major coronary artery or significant branch, verified by coronary angiography;
  • For acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) patients: clinical stability meeting discharge criteria post-treatment;
  • Voluntary participation with signed .

Exclusion criteria

Exclusion Criteria:

  • Heart transplant recipients;
  • Severe systemic comorbidities with \<1 year;
  • Previous enrollment in other drug/device clinical trials without completing the primary endpoint observation period;
  • Inability to comply with follow-up (e.g., dementia, severe psychiatric disorders).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. MACCE, defined as a composite of cardiac death, MI, ischemic stroke, and repeat revascularization

    Time frame: 2 years

  2. Sensitivity for 2-year MACCE prediction

    For the validation cohort

    Time frame: 2 years

  3. Specificity for 2-year MACCE prediction

    For the validation cohort

    Time frame: 2 years

Secondary outcomes

  1. Incidence of death (cardiovascular, noncardiovascular, and undetermined) at 1 m, 6 m, 1 y and 2 y

    For the development cohort

    Time frame: 2 years

  2. Incidence of MI (target vessel related and non-target vessel related or Culprit and non-culprit lesion-related) at 1 m, 6 m, 1 y and 2 y

    For the development cohort

    Time frame: 2 years

  3. Incidence of all revascularizations (ischemia driven vs. non-ischemia driven; Target vs. non-target vessel; Culprit vs. non-culprit lesion) at 1 m, 6 m, 1 y and 2 y

    For the development cohort

    Time frame: 2 years

  4. Incidence of definite or probable stent thrombosis during the acute, subacute, late, and very late phase according to the ARC-2 criteria

    For the development cohort

    Time frame: 2 years

  5. Incidence of stroke (ischemic and hemorrhagic stroke) at 1 m, 6 m, 1 y and 2 y

    For the development cohort

    Time frame: 2 years

  6. Incidence of bleeding events defined as BARC type ≥2 at 1 m, 6 m, 1 y and 2 y

    For the development cohort

    Time frame: 2 years

  7. Area under the ROC curve (AUC)

    For the validation cohort

    Time frame: 2 years

  8. Positive predictive value (PPV)

    For the validation cohort

    Time frame: 2 years

  9. Negative predictive value (NPV)

    For the validation cohort

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jul 2027, 28 months after the start.

Of 132 non-industry observational studies under Coronary Disease, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 192. This study's planned 28 months is below that.

Counting every sponsor, half of 154 studies reached it within 47 months; a quarter within 21 and three quarters within 123.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 4, 2025
StartActual
Mar 31, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07004452
Responsible party
Sponsor
First posted
Jun 4, 2025
Start date
Mar 31, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jun 4, 2025

Study contacts

Jingjing Xu
Contact
335418449@qq.com
86 134-260-50924

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion